JPWO2020225551A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020225551A5 JPWO2020225551A5 JP2021566070A JP2021566070A JPWO2020225551A5 JP WO2020225551 A5 JPWO2020225551 A5 JP WO2020225551A5 JP 2021566070 A JP2021566070 A JP 2021566070A JP 2021566070 A JP2021566070 A JP 2021566070A JP WO2020225551 A5 JPWO2020225551 A5 JP WO2020225551A5
- Authority
- JP
- Japan
- Prior art keywords
- chromosomal
- dlbcl
- interactions
- markers
- samples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002759 chromosomal effect Effects 0.000 claims description 315
- 230000003993 interaction Effects 0.000 claims description 247
- 150000007523 nucleic acids Chemical class 0.000 claims description 165
- 238000000034 method Methods 0.000 claims description 162
- 239000000523 sample Substances 0.000 claims description 154
- 206010060862 Prostate cancer Diseases 0.000 claims description 150
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 150
- 102000039446 nucleic acids Human genes 0.000 claims description 148
- 108020004707 nucleic acids Proteins 0.000 claims description 148
- 108090000623 proteins and genes Proteins 0.000 claims description 126
- 230000008569 process Effects 0.000 claims description 93
- 108020004414 DNA Proteins 0.000 claims description 48
- 238000004393 prognosis Methods 0.000 claims description 48
- 238000001514 detection method Methods 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 34
- 210000000349 chromosome Anatomy 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 21
- 238000012216 screening Methods 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 241000282472 Canis lupus familiaris Species 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 13
- 238000013461 design Methods 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 238000003753 real-time PCR Methods 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 6
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 238000011895 specific detection Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 156
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 153
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 66
- 201000010099 disease Diseases 0.000 description 65
- 238000003752 polymerase chain reaction Methods 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 57
- 239000008280 blood Substances 0.000 description 57
- 239000003550 marker Substances 0.000 description 56
- 238000012360 testing method Methods 0.000 description 50
- 239000000090 biomarker Substances 0.000 description 48
- 230000001973 epigenetic effect Effects 0.000 description 47
- 238000003556 assay Methods 0.000 description 45
- 230000004083 survival effect Effects 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 32
- 238000013459 approach Methods 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 29
- 239000012634 fragment Substances 0.000 description 26
- 230000035945 sensitivity Effects 0.000 description 25
- 238000003491 array Methods 0.000 description 23
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 20
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 206010025323 Lymphomas Diseases 0.000 description 19
- 238000000513 principal component analysis Methods 0.000 description 19
- 238000001574 biopsy Methods 0.000 description 18
- 238000003745 diagnosis Methods 0.000 description 18
- 238000002493 microarray Methods 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 108010008707 Mucin-1 Proteins 0.000 description 14
- 102000007298 Mucin-1 Human genes 0.000 description 14
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 description 14
- 101710102693 Solute carrier family 22 member 3 Proteins 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 238000013517 stratification Methods 0.000 description 14
- 102100037768 Acetyl-CoA acetyltransferase, mitochondrial Human genes 0.000 description 13
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 description 13
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 description 13
- 101710084102 Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000007857 nested PCR Methods 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 238000010200 validation analysis Methods 0.000 description 13
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 12
- 102100035251 Protein C-ets-1 Human genes 0.000 description 12
- 108010077544 Chromatin Proteins 0.000 description 11
- 210000003483 chromatin Anatomy 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 108090000552 Caspase-2 Proteins 0.000 description 10
- 238000009534 blood test Methods 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 241000282465 Canis Species 0.000 description 9
- 102000004046 Caspase-2 Human genes 0.000 description 9
- 238000011223 gene expression profiling Methods 0.000 description 9
- 239000013610 patient sample Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 102100029983 Transcriptional regulator ERG Human genes 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000001794 hormone therapy Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 8
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 7
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003831 deregulation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000010837 poor prognosis Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 6
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 6
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010067083 3 beta-hydroxysteroid dehydrogenase type II Proteins 0.000 description 5
- 102100028118 Annexin A11 Human genes 0.000 description 5
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 5
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 description 5
- 101000768066 Homo sapiens Annexin A11 Proteins 0.000 description 5
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 description 5
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 description 5
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 5
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 5
- 102100039081 Steroid Delta-isomerase Human genes 0.000 description 5
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 210000001280 germinal center Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 108091027963 non-coding RNA Proteins 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 4
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 4
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 4
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000092 prognostic biomarker Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 3
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000000104 diagnostic biomarker Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 2
- 101150044146 CASP2 gene Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100478715 Drosophila melanogaster Start1 gene Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100440286 Mus musculus Cntrl gene Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000004076 epigenetic alteration Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 238000003012 network analysis Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011472 radical prostatectomy Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010089941 Apoptosomes Proteins 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000040848 ETS family Human genes 0.000 description 1
- 108091071901 ETS family Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 108010018070 Proto-Oncogene Proteins c-ets Proteins 0.000 description 1
- 102000004053 Proto-Oncogene Proteins c-ets Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710121478 Transcriptional repressor CTCF Proteins 0.000 description 1
- 102000007150 Tumor Necrosis Factor alpha-Induced Protein 3 Human genes 0.000 description 1
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- MHHMNDJIDRZZNT-UHFFFAOYSA-N atto 680 Chemical compound OC(=O)CCCN1C(C)(C)C=C(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 MHHMNDJIDRZZNT-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000035612 epigenetic expression Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012105 stratification Analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024211835A JP2025032205A (ja) | 2019-05-08 | 2024-12-04 | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906487.2A GB201906487D0 (en) | 2019-05-08 | 2019-05-08 | DNA Marker |
| GB1906487.2 | 2019-05-08 | ||
| GB1914729.7 | 2019-10-11 | ||
| GB201914729A GB201914729D0 (en) | 2019-10-11 | 2019-10-11 | DNA marker |
| GB2006286.5 | 2020-04-29 | ||
| GBGB2006286.5A GB202006286D0 (en) | 2020-04-29 | 2020-04-29 | DNA marker |
| PCT/GB2020/051105 WO2020225551A1 (en) | 2019-05-08 | 2020-05-06 | Chromosome conformation markers of prostate cancer and lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024211835A Division JP2025032205A (ja) | 2019-05-08 | 2024-12-04 | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532108A JP2022532108A (ja) | 2022-07-13 |
| JP2022532108A5 JP2022532108A5 (https=) | 2023-05-16 |
| JPWO2020225551A5 true JPWO2020225551A5 (https=) | 2023-05-16 |
| JP7617029B2 JP7617029B2 (ja) | 2025-01-17 |
Family
ID=70775424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566070A Active JP7617029B2 (ja) | 2019-05-08 | 2020-05-06 | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
| JP2024211835A Pending JP2025032205A (ja) | 2019-05-08 | 2024-12-04 | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024211835A Pending JP2025032205A (ja) | 2019-05-08 | 2024-12-04 | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230049379A1 (https=) |
| EP (1) | EP3966350A1 (https=) |
| JP (2) | JP7617029B2 (https=) |
| KR (1) | KR20220007132A (https=) |
| CN (2) | CN120591403A (https=) |
| AU (3) | AU2020268861B2 (https=) |
| CA (1) | CA3138719A1 (https=) |
| GB (3) | GB2626699B (https=) |
| IL (1) | IL287597A (https=) |
| MY (1) | MY203765A (https=) |
| SG (1) | SG11202112221TA (https=) |
| TW (1) | TWI873135B (https=) |
| WO (1) | WO2020225551A1 (https=) |
| ZA (1) | ZA202109658B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302862A (zh) * | 2021-03-04 | 2023-01-16 | 英商牛津生物力學公眾有限公司 | 染色體交互作用標記物 |
| WO2025215190A1 (en) * | 2024-04-12 | 2025-10-16 | Oxford BioDynamics PLC | Method of typing chromosome markers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2704625A1 (en) * | 2007-11-08 | 2009-05-14 | University Of Washington | Dna microarray based identification and mapping of balanced translocation breakpoints |
| US10364469B2 (en) * | 2014-01-16 | 2019-07-30 | Illumina, Inc | Gene expression panel for prognosis of prostate cancer recurrence |
| WO2016193110A1 (en) * | 2015-05-29 | 2016-12-08 | Koninklijke Philips N.V. | Methods of prostate cancer prognosis |
| US11802305B2 (en) * | 2015-06-24 | 2023-10-31 | Oxford BioDynamics PLC | Detection processes using sites of chromosome interaction |
| MY190153A (en) * | 2016-12-01 | 2022-03-31 | Oxford BioDynamics PLC | Application of epigenetic chromosomal interactions in cancer diagnostics |
-
2020
- 2020-05-06 US US17/609,273 patent/US20230049379A1/en active Pending
- 2020-05-06 EP EP20726912.7A patent/EP3966350A1/en active Pending
- 2020-05-06 GB GB2406403.2A patent/GB2626699B/en active Active
- 2020-05-06 SG SG11202112221TA patent/SG11202112221TA/en unknown
- 2020-05-06 CN CN202510697824.7A patent/CN120591403A/zh active Pending
- 2020-05-06 GB GB2117415.6A patent/GB2597895B/en active Active
- 2020-05-06 AU AU2020268861A patent/AU2020268861B2/en active Active
- 2020-05-06 JP JP2021566070A patent/JP7617029B2/ja active Active
- 2020-05-06 GB GBGB2117415.6D patent/GB202117415D0/en active Pending
- 2020-05-06 MY MYPI2021006427A patent/MY203765A/en unknown
- 2020-05-06 WO PCT/GB2020/051105 patent/WO2020225551A1/en not_active Ceased
- 2020-05-06 CN CN202080044081.9A patent/CN114008218B/zh active Active
- 2020-05-06 KR KR1020217040317A patent/KR20220007132A/ko active Pending
- 2020-05-06 CA CA3138719A patent/CA3138719A1/en active Pending
- 2020-05-07 TW TW109115266A patent/TWI873135B/zh active
-
2021
- 2021-10-26 IL IL287597A patent/IL287597A/en unknown
- 2021-11-26 ZA ZA2021/09658A patent/ZA202109658B/en unknown
- 2021-12-14 AU AU2021286283A patent/AU2021286283B2/en active Active
- 2021-12-14 AU AU2021286282A patent/AU2021286282B2/en active Active
-
2024
- 2024-12-04 JP JP2024211835A patent/JP2025032205A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7813140B2 (ja) | 病原体検出のための配列決定データを使用するためのシステムおよび方法 | |
| JP7631400B2 (ja) | 遺伝子調節 | |
| WO2017077499A1 (en) | Biomarkers of squamous cell carcinoma of head and neck, prognostic markers of recurrence in squamous cell carcinoma of head and neck, and methods thereof | |
| EP2121988B1 (en) | Prostate cancer survival and recurrence | |
| EP4320618A2 (en) | Cell-free dna sequence data analysis method to examine nucleosome protection and chromatin accessibility | |
| JP2025032205A (ja) | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー | |
| JP2021526375A (ja) | 検出方法 | |
| US20260002208A1 (en) | Chromosome interactions | |
| ES3029416T3 (en) | Chromosome interaction markers | |
| JPWO2020225551A5 (https=) | ||
| Hayward et al. | The role of DNA methylation in stratifying and understanding nephrotic syndrome | |
| CN117795098A (zh) | 染色体相互作用标志物 | |
| TW202548029A (zh) | 染色體標記測試 |